Algernon Pharmaceuticals Equity (AGN_t)

Currency in CAD
0.01
0.00(0.00%)
Closed·
Showing Algernon historical data. For real-time data please try another search
Day's Range
0.010.01
52 wk Range
0.010.01
Key Statistics
Bid/Ask
0.01 / 0.10
Prev. Close
0.12
Open
0.01
Day's Range
0.01-0.01
52 wk Range
0.01-0.01
Volume
-
Average Volume (3m)
0
1-Year Change
0%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Algernon Pharmaceuticals Equity Company Profile

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

0
Market
Canada

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AGN_t Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.